5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
Cardiovascular O
Reactions O
: O
Sudden O
death O
has O
been O
reported O
in O
association O
with O
CNS O
stimulant O
treatment O
at O
recommended O
doses O
in O
pediatric O
patients O
with O
structural O
cardiac O
abnormalities O
or O
other O
serious O
heart O
problems O
. O

In O
adults O
, O
sudden O
death O
, O
stroke O
, O
and O
myocardial O
infarction O
have O
been O
reported O
. O

Avoid O
use O
in O
patients O
with O
known O
structural O
cardiac O
abnormalities O
, O
cardiomyopathy O
, O
serious O
heart O
arrhythmia O
, O
or O
coronary O
artery O
disease O
( O
5.2 O
) O
* O
Blood O
Pressure O
and O
Heart O
Rate O
Increases O
: O
Monitor O
blood O
pressure O
and O
pulse O
. O

Consider O
benefits O
and O
risks O
before O
use O
in O
patients O
for O
whom O
blood O
pressure O
increases O
may O
be O
problematic O
( O
5.3 O
) O
* O
Psychiatric O
Adverse O
Reactions O
: O
May O
cause O
psychotic O
or O
manic O
symptoms O
in O
patients O
with O
no O
prior O
history O
, O
or O
exacerbation O
of O
symptoms O
in O
patients O
with O
pre-existing O
psychosis O
. O

Evaluate O
for O
bipolar O
disorder O
prior O
to O
stimulant O
use O
( O
5.4 O
) O
* O
Suppression O
of O
Growth O
: O
Monitor O
height O
and O
weight O
in O
pediatric O
patients O
during O
treatment O
( O
5.5 O
) O
* O
Peripheral O
Vasculopathy O
, O
including O
Raynaud O
's O
phenomenon O
: O
Stimulants O
are O
associated O
with O
peripheral O
vasculopathy O
, O
including O
Raynaud O
's O
phenomenon O
. O

Careful O
observation O
for O
digital O
changes O
is O
necessary O
during O
treatment O
with O
stimulants O
( O
5.6 O
) O
* O
Serotonin O
Syndrome O
: O
Increased O
risk O
when O
co-administered O
with O
serotonergic O
agents O
( O
e.g. O
, O
SSRIs O
, O
SNRIs O
, O
triptans O
) O
, O
but O
also O
during O
overdosage O
situations O
. O

If O
it O
occurs O
, O
discontinue O
VYVANSE O
and O
initiate O
supportive O
treatment O
( O
4 O
, O
5.7 O
, O
10 O
) O
. O

5.1 O
Potential O
for O
Abuse O
and O
Dependence O
CNS O
stimulants O
( O
amphetamines O
and O
methylphenidate-containing O
products O
) O
, O
including O
VYVANSE O
, O
have O
a O
high O
potential O
for O
abuse B-OSE_Labeled_AE
and O
dependence B-OSE_Labeled_AE
. O

Assess O
the O
risk O
of O
abuse B-NonOSE_AE
prior O
to O
prescribing O
, O
and O
monitor O
for O
signs O
of O
abuse B-NonOSE_AE
and O
dependence B-NonOSE_AE
while O
on O
therapy O
[ O
see O
Drug B-NonOSE_AE
Abuse I-NonOSE_AE
and O
Dependence B-NonOSE_AE
( O
9.2 O
, O
9.3 O
) O
] O
. O

5.2 O
Serious O
Cardiovascular B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
and O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
have O
been O
reported O
in O
adults O
with O
CNS O
stimulant O
treatment O
at O
recommended O
doses O
. O

Sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
has O
been O
reported O
in O
children O
and O
adolescents O
with O
structural B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
and O
other O
serious O
heart B-Not_AE_Candidate
problems I-Not_AE_Candidate
taking O
CNS O
stimulants O
at O
recommended O
doses O
for O
ADHD B-Not_AE_Candidate
. O

Avoid O
use O
in O
patients O
with O
known O
structural B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
cardiomyopathy B-Not_AE_Candidate
, O
serious O
heart B-Not_AE_Candidate
arrhythmia I-Not_AE_Candidate
, O
coronary B-Not_AE_Candidate
artery I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
and O
other O
serious O
heart B-Not_AE_Candidate
problems I-Not_AE_Candidate
. O

Further O
evaluate O
patients O
who O
develop O
exertional B-NonOSE_AE
chest I-NonOSE_AE
pain I-NonOSE_AE
, O
unexplained B-NonOSE_AE
syncope I-NonOSE_AE
, O
or O
arrhythmias B-NonOSE_AE
during O
VYVANSE O
treatment O
. O

5.3 O
Blood O
Pressure O
and O
Heart O
Rate O
Increases O
CNS O
stimulants O
cause O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
mean O
increase O
about O
2-4 O
mm O
Hg O
) O
and O
heart O
rate O
( O
mean O
increase O
about O
3-6 O
bpm O
) O
. O

Monitor O
all O
patients O
for O
potential O
tachycardia B-NonOSE_AE
and O
hypertension B-NonOSE_AE
. O

5.4 O
Psychiatric B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
Psychosis I-OSE_Labeled_AE
CNS O
stimulants O
may O
exacerbate B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
of I-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
and O
thought O
disorder O
in O
patients O
with O
a O
pre-existing O
psychotic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Induction O
of O
a O
Manic O
Episode O
in O
Patients O
with O
Bipolar O
Disorder O
CNS O
stimulants O
may O
induce O
a O
mixed B-OSE_Labeled_AE
/manic O
episode I-OSE_Labeled_AE
in I-OSE_Labeled_AE
patients I-OSE_Labeled_AE
with I-OSE_Labeled_AE
bipolar I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Prior O
to O
initiating O
treatment O
, O
screen O
patients O
for O
risk O
factors O
for O
developing O
a O
manic B-NonOSE_AE
episode I-NonOSE_AE
( O
e.g. O
, O
comorbid O
or O
history O
of O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
or O
a O
family O
history O
of O
suicide B-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
) O
. O

New O
Psychotic O
or O
Manic O
Symptoms O
CNS O
stimulants O
, O
at O
recommended O
doses O
, O
may O
cause O
psychotic B-OSE_Labeled_AE
or O
manic O
symptoms I-OSE_Labeled_AE
, O
e.g O
. O

hallucinations B-OSE_Labeled_AE
, O
delusional B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
, O
or O
mania B-OSE_Labeled_AE
in O
children O
and O
adolescents O
without O
a O
prior O
history O
of O
psychotic B-Not_AE_Candidate
illness I-Not_AE_Candidate
or O
mania B-Not_AE_Candidate
. O

If O
such O
symptoms O
occur O
, O
consider O
discontinuing O
VYVANSE O
. O

In O
a O
pooled O
analysis O
of O
multiple O
short-term O
, O
placebo-controlled O
studies O
of O
CNS O
stimulants O
, O
psychotic B-OSE_Labeled_AE
or O
manic O
symptoms I-OSE_Labeled_AE
occurred O
in O
0.1 O
% O
of O
CNS O
stimulant-treated O
patients O
compared O
to O
0 O
% O
in O
placebo-treated O
patients O
. O

5.5 O
Suppression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Growth I-OSE_Labeled_AE
CNS O
stimulants O
have O
been O
associated O
with O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
and O
slowing B-OSE_Labeled_AE
of I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
in O
pediatric O
patients O
. O

Closely O
monitor O
growth O
( O
weight O
and O
height O
) O
in O
pediatric O
patients O
treated O
with O
CNS O
stimulants O
, O
including O
VYVANSE O
. O

In O
a O
4-week O
, O
placebo-controlled O
trial O
of O
VYVANSE O
in O
patients O
ages O
6 O
to O
12 O
years O
old O
with O
ADHD B-Not_AE_Candidate
, O
there O
was O
a O
dose-related O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
in O
the O
VYVANSE O
groups O
compared O
to O
weight B-NonOSE_AE
gain I-NonOSE_AE
in O
the O
placebo O
group O
. O

Additionally O
, O
in O
studies O
of O
another O
stimulant O
, O
there O
was O
slowing B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
increase I-NonOSE_AE
in I-NonOSE_AE
height I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.6 O
Peripheral O
Vasculopathy O
, O
including O
Raynaud O
's O
Phenomenon O
Stimulants O
, O
including O
VYVANSE O
, O
are O
associated O
with O
peripheral B-OSE_Labeled_AE
vasculopathy I-OSE_Labeled_AE
, O
including O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
. O

Signs O
and O
symptoms O
are O
usually O
intermittent O
and O
mild O
; O
however O
, O
very O
rare O
sequelae O
include O
digital B-NonOSE_AE
ulceration I-NonOSE_AE
and/or O
soft B-NonOSE_AE
tissue I-NonOSE_AE
breakdown I-NonOSE_AE
. O

Effects O
of O
peripheral B-OSE_Labeled_AE
vasculopathy I-OSE_Labeled_AE
, O
including O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
, O
were O
observed O
in O
post-marketing O
reports O
at O
different O
times O
and O
at O
therapeutic O
doses O
in O
all O
age O
groups O
throughout O
the O
course O
of O
treatment O
. O

Signs O
and O
symptoms O
generally O
improve O
after O
reduction O
in O
dose O
or O
discontinuation O
of O
drug O
. O

Careful O
observation O
for O
digital B-NonOSE_AE
changes I-NonOSE_AE
is O
necessary O
during O
treatment O
with O
stimulants O
. O

Further O
clinical O
evaluation O
( O
e.g. O
, O
rheumatology O
referral O
) O
may O
be O
appropriate O
for O
certain O
patients O
. O

5.7 O
Serotonin O
Syndrome O
Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
a O
potentially O
life-threatening O
reaction O
, O
may O
occur O
when O
amphetamines O
are O
used O
in O
combination O
with O
other O
drugs O
that O
affect O
the O
serotonergic O
neurotransmitter O
systems O
such O
as O
monoamine O
oxidase O
inhibitors O
( O
MAOIs O
) O
, O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
, O
serotonin O
norepinephrine O
reuptake O
inhibitors O
( O
SNRIs O
) O
, O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
and O
St O
. O
John O
's O
Wort O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Amphetamines O
and O
amphetamine O
derivatives O
are O
known O
to O
be O
metabolized O
, O
to O
some O
degree O
, O
by O
cytochrome O
P450 O
2D6 O
( O
CYP2D6 O
) O
and O
display O
minor O
inhibition O
of O
CYP2D6 O
metabolism O
[ O
see O
Clinical O
Pharmacology O
12.3 O
] O
. O

The O
potential O
for O
a O
pharmacokinetic O
interaction O
exists O
with O
the O
co-administration O
of O
CYP2D6 O
inhibitors O
which O
may O
increase O
the O
risk O
with O
increased O
exposure O
to O
the O
active O
metabolite O
of O
VYVANSE O
( O
dextroamphetamine O
) O
. O

In O
these O
situations O
, O
consider O
an O
alternative O
non-serotonergic O
drug O
or O
an O
alternative O
drug O
that O
does O
not O
inhibit O
CYP2D6 O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
, O
seizures B-NonOSE_AE
, O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Concomitant O
use O
of O
VYVANSE O
with O
MAOI O
drugs O
is O
contraindicated O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Discontinue O
treatment O
with O
VYVANSE O
and O
any O
concomitant O
serotonergic O
agents O
immediately O
if O
symptoms O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
occur O
, O
and O
initiate O
supportive O
symptomatic O
treatment O
. O

Concomitant O
use O
of O
VYVANSE O
with O
other O
serotonergic O
drugs O
or O
CYP2D6 O
inhibitors O
should O
be O
used O
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk O
. O

If O
clinically O
warranted O
, O
consider O
initiating O
VYVANSE O
with O
lower O
doses O
, O
monitoring O
patients O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
during O
drug O
initiation O
or O
titration O
, O
and O
informing O
patients O
of O
the O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

